Limitations of small x resummation methods from F2data

We discuss several methods of calculating the DIS structure functions F2(x,Q2) based on BFKL-type small x resummations. Taking into account new HERA data ranging down to small xand low Q2, the pure leading order BFKL-based approach is excluded. Other methods based on high energy factorization are closer to conventional renormalization group equations. Despite several difficulties and ambiguities in combining the renormalization group equations with small x resummed terms, we find that a fit to the current data is hardly feasible, since the data in the low Q2 region are not as steep as the BFKL formalism predicts. Thus we conclude that deviations from the (successful) renormalization group approach towards summing up logarithms in 1/x are disfavoured by experiment.

Small x resummations confronted with F2(x, Q2) data

It has been observed recently that a consistent LO BFKL gluon evolution leads to a steep growth of F2(x, Q2) for x → 0 almost independently of Q2. We show that current data from the DESY HERA collider are precise enough to finally rule out a pure BFKL behaviour in the accessible small x region. Several attempts have been made by other groups to treat the BFKL type small x resummations instead as additions to the conventional anomalous dimensions of the successful renormalization group “Altarelli-Parisi” equations. We demonstrate that all presently available F2 data, in particular at lower values of Q2, can not be described using the presently known NLO (two-loop consistent) small x resummations. Finally we comment on the common reason for the failure of these BFKL inspired methods which result, in general, in too steep >x-dependencies as x → 0.

Balitskiǐ-Fadin-Kuraev-Lipatov equation versus data from DESY HERA

The BFKL equation and the kT-factorization theorem are used to obtain predictions for F2 in the small Bjo/rken-x region over a wide range of Q2. The dependence on the parameters, especially on those concerning the infrared region, is discussed. After a background fit to recent experimental data obtained at DESY HERA and at Fermilab (E665 experiment) we find that the predicted, almost Q2 independent BFKL slope λ≳0.5 appears to be too steep at lower Q2 values. Thus there seems to be a chance that future HERA data can distinguish between pure BFKL and conventional field theoretic renormalization group approaches. © 1995 The American Physical Society.

Ordering on multiple lengthscales in a series of side group liquid crystal block copolymers containing a cholesteryl-based mesogen

Hierarchical ordering in a side group liquid crystal block copolymer is investigated by differential scanning calorimetry, polarized optical microscopy, small-angle X-ray and neutron scattering (SAXS and SANS) and transmission electron microscopy (TEM). A series of block copolymers with a range of compositions was prepared by atom transfer radical polymerization, comprising a polystyrene block and a poly(methyl methacrylate) block bearing chiral cholesteryl mesogens. Smectic ordering is observed as well as microphase separation of the block copolymer. Lamellar structures were observed for far larger volume fractions than for coil-coil copolymers (up to a volume fraction of liquid crystal block, f(LC) = 0.8). A sample with f(LC) = 0.86 exhibited a hexagonal-packed cylinder morphology, as confirmed by SAXS and TEM. The matrix comprised the liquid crystal block, with the mesogens forming smectic layers. For the liquid crystal homopolymer and samples with high f(LC), a smectic-smectic phase transition was observed below the clearing point. At low temperature, the smectic phase comprises coexisting domains with monolayer S-A,S-1 coexisting with interdigitated S-A,S-d domains. At high temperature a SA,1 phase is observed. This is the only structure observed for samples with lower f(LC). These unprecedented results point to the influence of block copolymer microphase separation on the smectic ordering.

A new calibrated sunspot group series since 1749: statistics of active day fractions

Although the sunspot-number series have existed since the mid-19th century, they are still the subject of intense debate, with the largest uncertainty being related to the "calibration" of the visual acuity of individual observers in the past. Daisy-chain regression methods are applied to inter-calibrate the observers which may lead to significant bias and error accumulation. Here we present a novel method to calibrate the visual acuity of the key observers to the reference data set of Royal Greenwich Observatory sunspot groups for the period 1900-1976, using the statistics of the active-day fraction. For each observer we independently evaluate their observational thresholds [S_S] defined such that the observer is assumed to miss all of the groups with an area smaller than S_S and report all the groups larger than S_S. Next, using a Monte-Carlo method we construct, from the reference data set, a correction matrix for each observer. The correction matrices are significantly non-linear and cannot be approximated by a linear regression or proportionality. We emphasize that corrections based on a linear proportionality between annually averaged data lead to serious biases and distortions of the data. The correction matrices are applied to the original sunspot group records for each day, and finally the composite corrected series is produced for the period since 1748. The corrected series displays secular minima around 1800 (Dalton minimum) and 1900 (Gleissberg minimum), as well as the Modern grand maximum of activity in the second half of the 20th century. The uniqueness of the grand maximum is confirmed for the last 250 years. It is shown that the adoption of a linear relationship between the data of Wolf and Wolfer results in grossly inflated group numbers in the 18th and 19th centuries in some reconstructions.

Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology

The failing heart is characterized by complex tissue remodelling involving increased cardiomyocyte death, and impairment of sarcomere function, metabolic activity, endothelial and vascular function, together with increased inflammation and interstitial fibrosis. For years, therapeutic approaches for heart failure (HF) relied on vasodilators and diuretics which relieve cardiac workload and HF symptoms. The introduction in the clinic of drugs interfering with beta-adrenergic and angiotensin signalling have ameliorated survival by interfering with the intimate mechanism of cardiac compensation. Current therapy, though, still has a limited capacity to restore muscle function fully, and the development of novel therapeutic targets is still an important medical need. Recent progress in understanding the molecular basis of myocardial dysfunction in HF is paving the way for development of new treatments capable of restoring muscle function and targeting specific pathological subsets of LV dysfunction. These include potentiating cardiomyocyte contractility, increasing cardiomyocyte survival and adaptive hypertrophy, increasing oxygen and nutrition supply by sustaining vessel formation, and reducing ventricular stiffness by favourable extracellular matrix remodelling. Here, we consider drugs such as omecamtiv mecarbil, nitroxyl donors, cyclosporin A, SERCA2a (sarcoplasmic/endoplasmic Ca(2 +) ATPase 2a), neuregulin, and bromocriptine, all of which are currently in clinical trials as potential HF therapies, and discuss novel molecular targets with potential therapeutic impact that are in the pre-clinical phases of investigation. Finally, we consider conceptual changes in basic science approaches to improve their translation into successful clinical applications.